Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 13/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.52 |
| ▸ | MTOR | P42345 | 2/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.52 |
| ▸ | HPGDS | O60760 | 2/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3336059 | 1.00 | CD274 (0.54) | CD274HPGDPIK3CAMTORPIK3CG | |
| SCHEMBL3335087 | 0.95 | PIK3CA (0.54) | CD274HPGDPIK3CAMTORPIK3CG | |
| SCHEMBL3335079 | 0.95 | PIK3CA (0.54) | CD274HPGDPIK3CAMTORPIK3CG | |
| SCHEMBL5131249 | 0.92 | PIK3CA (0.51) | CD274HPGDPIK3CAMTORPIK3CG | |
| SCHEMBL3335092 | 0.91 | PIK3CA (0.50) | CD274HPGDPIK3CAMTORPIK3CG | |
| SCHEMBL3335090 | 0.91 | PIK3CA (0.50) | CD274HPGDPIK3CAMTORPIK3CG | |
| SCHEMBL823780 | 0.87 | PIK3CA (0.51) | CD274HPGDPIK3CAMTORPIK3CG | |
| SCHEMBL826378 | 0.87 | PIK3CA (0.51) | CD274HPGDPIK3CAMTORPIK3CG | |
| SCHEMBL3335713 | 0.87 | BRAF (0.48) | CD274PIK3CAMTORPIK3CGHPGDS | |
| SCHEMBL3335711 | 0.87 | BRAF (0.48) | CD274PIK3CAMTORPIK3CGHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673929-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | claimed |
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | claimed |
| US-8673929-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | OPRD1, IFNAR1, NR4A1 | CD274 3803/4885HPGD 3242/4885PIK3CA 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.